About celcuity inc - CELC
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
CELC At a Glance
Celcuity, Inc.
2800 Campus Drive
Minneapolis, Minnesota 55441
| Phone | 1-763-392-0767 | Revenue | 0.00 | |
| Industry | Medical Specialties | Net Income | -177,042,000.00 | |
| Sector | Health Technology | Employees | 155 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CELC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 47.854 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -26.415 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.071 |
CELC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,142,206.452 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CELC Liquidity
| Current Ratio | 10.547 |
| Quick Ratio | 10.547 |
| Cash Ratio | 9.999 |
CELC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -49.753 |
| Return on Equity | -163.796 |
| Return on Total Capital | -41.907 |
| Return on Invested Capital | -55.691 |
CELC Capital Structure
| Total Debt to Total Equity | 320.128 |
| Total Debt to Total Capital | 76.198 |
| Total Debt to Total Assets | 68.996 |
| Long-Term Debt to Equity | 320.075 |
| Long-Term Debt to Total Capital | 76.185 |